Amarin Corporation (AMRN) Q4 2025 earnings summary

Executive summary

• Achieved substantial cost reductions and narrowed losses through global restructuring and strategic initiatives, positioning for long-term growth and operational efficiency.

• Maintained U.S. market leadership for VASCEPA, retaining major managed care exclusives through 2025 and expanding European presence via a long-term partnership with Recordati, with IP protection through 2039.

• Returned to positive cash flow ahead of schedule, ending 2025 with a robust, debt-free balance sheet and $303 million in cash and investments.

• Expanded international presence through partnerships, securing regulatory approvals in South Korea and Singapore, and advancing filings in Southeast Asia.

Financial highlights

• Q4 2025 total net revenue was $49.2 million, down 21% year-over-year, with U.S. sales declining 7% due to net selling price decreases.

• Europe product revenue was $2.3 million, including $900,000 in supply shipments to Recordati; Rest of World revenues were $3.1 million, both down year-over-year due to prior year stocking orders.

• Licensing and royalty revenue increased 20% year-over-year to $2.7 million, driven by higher in-market sales from global partners.

• Q4 2025 operating expenses decreased 31% to $29.5 million, with SG&A down 46% and cost of goods sold dropping 63% due to restructuring.

• Q4 2025 operating loss narrowed to $2.3 million (excluding restructuring) or $6.3 million (reported), from $16 million and $52.5 million respectively in Q4 2024; net loss improved to $1.2 million.

• Ended 2025 with $303 million in cash and investments, no debt, and $455 million in working capital.

Outlook and guidance

• Expect to achieve the full $70 million in annualized operating expense savings by end of Q2 2026.

• Anticipate positive cash flow for full year 2026, supported by cost-efficient revenue generation and improved OpEx profile.

• 2026 will be a pivotal year, focusing on defending the U.S. franchise, expanding global presence, and unlocking long-term shareholder value.

• Continued investment in awareness and operational improvements from restructuring.